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TRAK correlated with LN dose, however, with linear regression R2 was 
less than 0.3 for all LNs which indicates that TRAK cannot be used to 
predict LN dose. 
 
 
Conclusions: BT contributes with considerable dose to pelvic LNs, and 
should be considered in the evaluation of total LN dose,in particular 
when pathological LNs are boosted. In our study the optimised 
BTcontributed with a range of 3.8 - 6.2Gy (D50%) to pelvic LN and 0.5-
1.9 to PAN,CI and ING (D50%). Image guided BT plan optimization had 
minor impact on BT contribution to LN dose.  
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Purpose/Objective: To assess the impact of organ movement and 
deformation on tumour and organ at risk (OAR) dose parameters by 
repeating MR imaging during individual brachytherapy (BT) fractions. 
Materials and Methods: Multiple MR scans during BT were performed 
in 12 patients treated with external beam radiotherapy (EBRT), 
chemotherapy and high dose rate (HDR) image guided adaptive BT. 
The BT schedule consisted of two HDR applications delivering two 
fractions each (2 times 2 fractions of 7Gy). A set of T2-weighted 
transversal, sagittal and coronal MR scans was acquired after insertion 
of the applicator (MRplan). High risk clinical target volume (HR-CTV) 
and the organs at risk (bladder, rectum, and sigmoid) were delineated 
and treatment planning was conducted directly on MR images. Prior to 
irradiation a second MRI set (MRprerad) was obtained. An onset 
applicator based registration with MRplan made evaluation of OAR 
position and volume changes before irradiation possible. Adaptations, 
e.g. deflating gas from the rectum, were applied to several patients 
to keep the rectum at MRprerad similar to the planned situation 
(MRplan). Applicator insertions, MR imaging and HDR dose delivery 
were performed in an adapted BT operation theatre, with afterloader 
secured to the wall. 
For research purposes the treatment plan was evaluated on the 
contours of MRprerad. Calculated dose differences between MRplan 
and MRprerad indicate changes between planned and received dose. 
These differences were evaluated and compared to the data obtained 
in a group of 10 patients that received repeated MR imaging during 
pulsed dose rate (PDR) BT.  
Results: The planned mean total dose (EBRT + BT) for the D90 HR-CTV 
and D2cc of bladder, rectum, and sigmoid were 86±6, 84±9, 64±9, and 
62±6 Gy EQD2, respectively. The mean differences between the 
planned dose and the received dose calculated on MRprerad were 
0.6±1.9, -0.7±3.6, 0.7±4.7, and 1.2±2.9 Gy EQD2, respectively. 
Analyses per HDR fraction (n=48) showed variety in physical mean 
dose differences; -1.0±3.7, -1.5±7.5, 2.6±18.6, and 4.7±21.8 %, 
respectively. The mean differences were small, but large ranges 
occurred especially for rectum and sigmoid of (-59-42) and (-34-76) %, 
respectively (figure1). However, despite these differences OAR 
constraints were exceeded in only 3 patients. Comparison with the 
PDR data showed a reduction of mean and standard-deviation of the 
calculated dose differences of the OAR. In particular for rectum and 
sigmoid, during PDR the mean differences increased systematically 20-
30% compared to only 3-5% in HDR treated patients.  
Conclusions: The introduction of MRprerad results in a more accurate 
estimate of the dose delivered to the patient. Visualization of 
anatomical changes prior to irradiation allows individualized 
interventions and adaptations which can reduce dose uncertainties in 
rectum and sigmoid.  
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Purpose/Objective: Little data exists on the effect of variations of 
bladder volume (BV) on toxicity outcomes for image-guided 
intracavitary brachytherapy (ICB) for cervical cancer. Limited data has 
shown that variable bladder filling at each fraction can vary the 
position of hot spots within the bladder. Recently, it has become our 
center's policy to alternate between small (60cc) and large (300cc) 
bladder filling with the assumption that this might reduce long-term 
bladder toxicity. Objective of this study was to determine if there was 
a correlation between BV variation and long-term bladder toxicity.  
Materials and Methods 
Data for patients treated with ICB from 2008 to 2012 in 3 centers was 
prospectively collected. Patients received 45 Gy in 25 fractions of 
pelvic ± para-aortic EBRT with concurrent chemotherapy followed by 4 
to 5 fractions of ICB. Patient-reported toxicity was measured with 
LENT-SOMA questionnaires at the time of follow-up visits. Dose 
parameters including HR-CTV D90 Bladder D2cc, ICRU bladder dose 
points and BV (based on CT contour) were recorded for each ICB 
fraction. A total dose in EQD2 was generated for each dose 
parameter. Standard deviation for bladder BV between the 4-5 
fractions in each patient was used as a surrogate measure of bladder 
volume variability. Univariate linear regression analyses were 
completed to determine if there was significant correlation between 
dose parameters or BV variabilty and LENT-SOMA bladder scores. 
Results: 79 patients were treated between 2008 and 2012 with ICB for 
cervical cancer with CT-based planning. 45 had stage I, 24 stage II, 9 
stage III and 1 stage IV. ICB dose was 30 Gy in 5 fractions of 6 Gy for 
85% of patients, 26Gy in 4 fractions of 6.5Gy for 7,5% and various 5 
fraction schedules of 26 to 32 Gy for 7.5%. Median follow-up was 22.4 
months. 42 patients had a LENT-SOMA bladder score of 0, 31 had 
grade 1 toxicity, 5 had grade 2 toxicity and 1 had grade 3 toxicity. 
Median total HR-CTV D90 EQD2 was 46.6 Gy10 for ICB alone and 90.6 
Gy10including contribution of EBRT. Median total bladder 2cc EQD2 for 
ICB was 36,9 Gy3. Median interfraction standard deviation (SD) of BV 
was 45.3cc (range: 3.7-178.6). All tests for HR-CTV D90, Bladder D2cc 
and ICRU bladder dose point were not statistically significant for 
correlation with LENT-SOMA bladder scores. Regression analysis for 
bladder volume SD vs.LENT-SOMA scores was statistically significant 
